Drug Developement/Delivery
- Global Sales of ADCs in 2022 – UP to 7 Billion
- FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx)
- EGFR-Directed ADCs for Cancer Treatment
- Kadcyla - Top-Selling Antibody Drug Conjugate (ADC)
- Learn More About ADCs From Its Structure
- ADC Drug Trodelvy Shows Positive Efficacy In three Types of Cancers
- HER2 Targeted Therapies In Breast Cancer
- FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) - First CD19-targeted ADC
- Blockbuster Drugs Approved by the FDA in August 2020
- FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer